Access the full text.
Sign up today, get DeepDyve free for 14 days.
Aaron Meadows, R. Pineda, L. Goodchild, T. Bobo, H. Fu (2019)
Threshold for Pre-existing Antibody Levels Limiting Transduction Efficiency of Systemic rAAV9 Gene Delivery: Relevance for TranslationMolecular Therapy. Methods & Clinical Development, 13
Shen Shen, K. Bryant, Junjiang Sun, Sarah Brown, Andrew Troupes, Nagesh Pulicherla, A. Asokan (2012)
Glycan Binding Avidity Determines the Systemic Fate of Adeno-Associated Virus Type 9Journal of Virology, 86
C. Hermanrud, M. Ryner, T. Luft, P. Jensen, Kathleen Ingenhoven, D. Rat, F. Deisenhammer, P. Sørensen, M. Pallardy, D. Sikkema, E. Bertotti, D. Kramer, P. Creeke, A. Fogdell-Hahn (2016)
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.Journal of immunological methods, 430
Lillian Falese, Krystal Sandza, B. Yates, S. Triffault, S. Gangar, B. Long, Laurie Tsuruda, Barrie Carter, Christian Vettermann, Stephen Zoog, Sylvia Fong (2017)
Strategy to detect pre-existing immunity to AAV gene therapyGene Therapy, 24
Alvydas Mikulskis, Dave Yeung, Weiping Chen, D. Mehta, L. Amaravadi (2013)
Novel data analysis methods to overcome cut point challenges and enable comprehensive assessment of antidrug binding activity in confirmatory assays.Journal of immunological methods, 392 1-2
Z. Fitzpatrick, C. Leborgne, E. Barbon, E. Masat, G. Ronzitti, L. Wittenberghe, A. Vignaud, F. Collaud, S. Charles, Marcelo Sola, F. Jouen, O. Boyer, F. Mingozzi (2018)
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector TransductionMolecular Therapy. Methods & Clinical Development, 9
Chengwen Li, Nattee Narkbunnam, Nattee Narkbunnam, R. Samulski, A. Asokan, G. Hu, L. Jacobson, M. Manco‐Johnson, P. Monahan, M. Manco‐Johnson, B. Riske, R. Kilcoyne, M. Manco-Johnson, S. Funk, L. Jacobson, J. Ingram, T. Abshire, T. Abshire, A. Shapiro, Michele Hacker, L. Valentino, W. Hoots, Deborah Brown, G. Buchanan, D. DiMichele, M. Recht, Cindy Leissinger, Shirley Bleak, Alan Cohen, P. Mathew, A. Matsunaga, D. Medeiros, D. Nugent, Gregory Thomas, A. Thompson, K. McRedmond, J. Soucie, H. Austin, B. Evatt (2011)
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophiliaGene Therapy, 19
W. McEwan, J. Tam, R. Watkinson, S. Bidgood, D. Mallery, L. James (2013)
Intracellular antibody-bound pathogens stimulate immune signaling via Fc-receptor TRIM21Nature immunology, 14
Bassel Akache, D. Grimm, K. Pandey, S. Yant, Hui Xu, M. Kay (2006)
The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9Journal of Virology, 80
D. Duan, Qiang Li, A. Kao, Y. Yue, J. Pessin, J. Engelhardt (1999)
Dynamin Is Required for Recombinant Adeno-Associated Virus Type 2 InfectionJournal of Virology, 73
Dan Wang, Li Zhong, Mengxin Li, Jia Li, K. Tran, Lingzhi Ren, R. He, Jun Xie, R. Moser, Cara Fraser, T. Kuchel, M. Sena-Esteves, T. Flotte, N. Aronin, G. Gao (2018)
Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene TransferMolecular Therapy. Methods & Clinical Development, 11
S. Boutin, Virginie Monteilhet, P. Véron, C. Leborgne, O. Benveniste, M. Montus, C. Masurier (2010)
Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.Human gene therapy, 21 6
C. Leborgne, V. Latournerie, S. Boutin, D. Desgué, Aliénor Quéré, Elodie Pignot, F. Collaud, S. Charles, Marcelo Sola, E. Masat, F. Jouen, O. Boyer, C. Masurier, F. Mingozzi, P. Véron (2019)
Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.Cellular immunology
F. Mingozzi, M. Maus, Daniel Hui, D. Sabatino, S. Murphy, J. Rasko, M. Ragni, C. Manno, J. Sommer, Haiyan Jiang, G. Pierce, H. Ertl, K. High (2007)
CD8+ T-cell responses to adeno-associated virus capsid in humansNature Medicine, 13
G. Berry, Giridhar Murlidharan, A. Asokan (2016)
30. Modulation of Intracellular Calcium Enhances AAV Transduction in the CNSMolecular Therapy, 24
G. Rogers, Ashley Martino, G. Aslanidi, G. Jayandharan, A. Srivastava, R. Herzog (2011)
Innate Immune Responses to AAV VectorsFrontiers in Microbiology, 2
C. Manno, V. Arruda, G. Pierce, B. Glader, M. Ragni, J. Rasko, M. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A. Zajko, J. Zehnder, H. Nakai, A. Chew, D. Leonard, D. Leonard, J. Wright, R. Lessard, J. Sommer, M. Tigges, D. Sabatino, A. Luk, Haiyan Jiang, F. Mingozzi, L. Couto, H. Ertl, K. High, K. High, M. Kay (2006)
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseNature Medicine, 12
Shalini Gupta, V. Devanarayan, D. Finco, G. Gunn, S. Kirshner, S. Richards, B. Rup, A. Song, M. Subramanyam (2011)
Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.Journal of pharmaceutical and biomedical analysis, 55 5
(2016)
Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product. Food and Drug Administration
Lindsey George, S. Sullivan, A. Giermasz, J. Rasko, B. Samelson-Jones, J. Ducore, A. Cuker, L. Sullivan, S. Majumdar, J. Teitel, C. McGuinn, M. Ragni, A. Luk, Daniel Hui, Fraser Wright, Yifeng Chen, Yun Liu, Katie Wachtel, Angela Winters, S. Tiefenbacher, V. Arruda, J. Loo, O. Zelenaia, D. Takefman, M. Carr, L. Couto, X. Anguela, K. High (2017)
Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX VariantThe New England Journal of Medicine, 377
R. Calcedo, H. Morizono, Lili Wang, R. McCarter, Jianping He, David Jones, M. Batshaw, James Wilson (2011)
Adeno-Associated Virus Antibody Profiles in Newborns, Children, and AdolescentsClinical and Vaccine Immunology, 18
P. Colella, G. Ronzitti, F. Mingozzi (2017)
Emerging Issues in AAV-Mediated In Vivo Gene TherapyMolecular Therapy. Methods & Clinical Development, 8
Sachiko Hirosue, K. Senn, N. Clément, M. Nonnenmacher, Laure Gigout, R. Linden, T. Weber (2007)
Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction.Virology, 367 1
B. Schultz, J. Chamberlain (2008)
Recombinant adeno-associated virus transduction and integration.Molecular therapy : the journal of the American Society of Gene Therapy, 16 7
Haiyan Jiang, L. Couto, Susannah Patarroyo-White, Tongyao Liu, D. Nagy, Joseph Vargas, Shangzhen Zhou, C. Scallan, J. Sommer, Sharmila Vijay, F. Mingozzi, K. High, G. Pierce (2006)
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.Blood, 108 10
C. Summerford, R. Samulski (1998)
Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 VirionsJournal of Virology, 72
Anita Kruzik, H. Koppensteiner, D. Fetahagic, Bettina Hartlieb, Sebastian Dorn, S. Romeder-Finger, S. Coulibaly, A. Weber, W. Hoellriegl, F. Horling, F. Scheiflinger, B. Reipert, Maurus Rosa (2019)
Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.Human gene therapy methods, 30 2
A. Cherukuri, H. Cahan, Greg Hart, A. Tuyl, P. Slasor, L. Bray, Joshua Henshaw, T. Ajayi, David Jacoby, C. O’Neill, B. Schweighardt (2018)
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.Clinical immunology, 197
D. Mallery, W. McEwan, S. Bidgood, G. Towers, Chris Johnson, L. James (2010)
Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)Proceedings of the National Academy of Sciences, 107
F. Schaarschmidt, M. Hofmann, T. Jaki, B. Grün, L. Hothorn (2015)
Statistical approaches for the determination of cut points in anti-drug antibody bioassays.Journal of immunological methods, 418
I. Virella-Lowell, A. Poirier, K. Chesnut, M. Brantly, T. Flotte (2000)
Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patientsGene Therapy, 7
M. Nonnenmacher, T. Weber (2012)
Intracellular transport of recombinant adeno-associated virus vectorsGene Therapy, 19
Ping-jie Xiao, A. Mitchell, Lu Huang, Chengwen Li, R. Samulski (2016)
Disruption of Microtubules Post-Virus Entry Enhances Adeno-Associated Virus Vector Transduction.Human gene therapy, 27 4
G. Shankar, V. Devanarayan, L. Amaravadi, Y. Barrett, R. Bowsher, D. Finco-Kent, M. Fiscella, B. Gorovits, Susan Kirschner, M. Moxness, T. Parish, V. Quarmby, Holly Smith, Wendell Smith, L. Zuckerman, E. Koren (2008)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.Journal of pharmaceutical and biomedical analysis, 48 5
Ashley Martino, Masataka Suzuki, D. Markusic, I. Zolotukhin, R. Ryals, B. Moghimi, H. Ertl, D. Muruve, Brendan Lee, R. Herzog (2011)
The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.Blood, 117 24
S. Murphy, Hojun Li, F. Mingozzi, D. Sabatino, Daniel Hui, S. Edmonson, K. High (2009)
Diverse IgG subclass responses to adeno‐associated virus infection and vector administrationJournal of Medical Virology, 81
Ping Guo, Junping Zhang, Matthew Chrzanowski, Jianhe Huang, Helen Chew, Jenni Firrman, N. Sang, Y. Diao, W. Xiao (2018)
Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding AssayMolecular Therapy. Methods & Clinical Development, 13
(2014)
In Vitro Companion Diagnostic Devices. Guidance for Industry and Food and Drug Administration Staff. Food and Drug Administration
B. Long, Krystal Sandza, Jennifer Holcomb, Lucy Crockett, Gregory Hayes, J. Arens, C. Fonck, L. Tsuruda, B. Schweighardt, C. O’Neill, Stephen Zoog, Christian Vettermann (2019)
The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene TherapyMolecular Therapy. Methods & Clinical Development, 13
M. Moskalenko, Lili Chen, M. Roey, B. Donahue, R. Snyder, J. Mcarthur, Salil Patel (2000)
Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus StructureJournal of Virology, 74
R. Thwaite, G. Pagès, M. Chillón, A. Bosch (2014)
AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapyGene Therapy, 22
Maria Bottermann, Stian Foss, Laurens Tienen, M. Vaysburd, James Cruickshank, K. O'connell, J. Clark, Keith Mayes, Katie Higginson, Jack Hirst, Martin McAdam, Greg Slodkowicz, E. Hutchinson, Patrycja Kozik, J. Andersen, L. James (2018)
TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccinationProceedings of the National Academy of Sciences of the United States of America, 115
Tingting Jiang, B. Xing, J. Rao (2008)
Recent Developments of Biological Reporter Technology for Detecting Gene ExpressionBiotechnology and Genetic Engineering Reviews, 25
C. Scallan, Haiyan Jiang, Tongyao Liu, Susannah Patarroyo-White, J. Sommer, Shangzhen Zhou, L. Couto, G. Pierce (2006)
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.Blood, 107 5
A. Majowicz, B. Nijmeijer, M. Lampen, Lisa Spronck, M. Haan, H. Petry, S. Deventer, C. Meyer, M. Tangelder, Valérie Ferreira (2019)
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABsMolecular Therapy. Methods & Clinical Development, 14
Christie Bell, L. Vandenberghe, Peter Bell, M. Limberis, G. Gao, Kim Vliet, M. Agbandje-McKenna, James Wilson (2011)
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice.The Journal of clinical investigation, 121 6
Seema Kumar, Jason DelCarpini, Q. Qu, M. Kane, B. Gorovits (2016)
Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay CutpointThe AAPS Journal, 19
F. Mingozzi, K. High (2013)
Immune responses to AAV vectors: overcoming barriers to successful gene therapy.Blood, 122 1
K. Woodard, Katharine Liang, William Bennett, R. Samulski (2016)
Heparan Sulfate Binding Promotes Accumulation of Intravitreally Delivered Adeno-associated Viral Vectors at the Retina for Enhanced Transduction but Weakly Influences TropismJournal of Virology, 90
V. Devanarayan, Wendell Smith, Rocco Brunelle, M. Seger, K. Krug, R. Bowsher (2017)
Recommendations for Systematic Statistical Computation of Immunogenicity Cut PointsThe AAPS Journal, 19
Masataka Suzuki, T. Bertin, G. Rogers, Racel Cela, I. Zolotukhin, D. Palmer, P. Ng, R. Herzog, Brendan Lee (2013)
Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.Molecular therapy : the journal of the American Society of Gene Therapy, 21 4
F. Mingozzi, K. High (2017)
Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape.Annual review of virology, 4 1
Amine Meliani, C. Leborgne, S. Triffault, L. Jeanson-Leh, P. Véron, F. Mingozzi (2015)
Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter SystemHuman Gene Therapy Methods, 26
S. Gray, S. Kalburgi, T. McCown, R. Samulski (2012)
Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human PrimatesGene therapy, 20
W. Ding, Liang Zhang, Ziying Yan, John Engelhardt (2005)
Intracellular trafficking of adeno-associated viral vectorsGene Therapy, 12
R. Calcedo, Jessica Chichester, James Wilson (2018)
Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors.Human gene therapy methods
T. Maclachlan, M. Milton, Oliver Turner, F. Tukov, V. Choi, Jan Penraat, M. Delmotte, Lydia Michaut, B. Jaffee, C. Bigelow (2017)
Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis PigmentosaMolecular Therapy. Methods & Clinical Development, 8
Y. Tseng, B. Gurda, P. Chipman, R. McKenna, S. Afione, J. Chiorini, N. Muzyczka, N. Olson, T. Baker, J. Kleinschmidt, M. Agbandje-McKenna (2014)
Adeno-Associated Virus Serotype 1 (AAV1)- and AAV5-Antibody Complex Structures Reveal Evolutionary Commonalities in Parvovirus Antigenic ReactivityJournal of Virology, 89
J. Bartlett, R. Wilcher, R. Samulski (2000)
Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus VectorsJournal of Virology, 74
Viral vector–based gene therapies (GTx) have received significant attention in the recent years and the number of ongoing GTx clinical trials is increasing. A platform of choice for many of these studies is adeno-associated virus (AAV). All humans may be exposed to natural AAV infections and could mount an immune response against the virus. Consequently, there can be a high prevalence of pre-existing anti-AAV immunity. This presents a potential limitation for AAV-based GTx due to the potential for AAV-specific antibodies to reduce the efficacy of the GTx. Therefore, appropriate assessment of potential subjects enrolled in these studies should include evaluation for the presence and degree of anti-AAV immunity, including anti-AAV neutralizing antibodies (NAb). Recommendations for the development and validation of cell-based anti-AAV NAb detection methods, including considerations related to selection of appropriate cell line, surrogate vector/reporter gene, assay matrix and controls, and methodologies for calculating assay cut-point are discussed herein. General recommendations for the key assay validation parameters are provided as well as considerations for the development of NAb diagnostic tests. This manuscript is produced by a group of scientists involved in GTx therapeutic development representing various companies. It is our intent to provide recommendations and guidance to industrial and academic laboratories working on viral vector based GTx modalities with the goal of achieving a more consistent approach to anti-AAV NAb assessment.
"The AAPS Journal" – Springer Journals
Published: Jan 6, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.